← All countries · Europe
92%
MCV1
2025 · WHO/UNICEF estimate
99%
DTP3
2025 · WHO/UNICEF estimate
99%
IPV complete
2025 · WHO/UNICEF estimate
99%
HepB3
2025 · WHO/UNICEF estimate
0
Measles cases
2025 reported
8
Pertussis (whooping cough) cases
2025 reported
Two kinds of number live on this page. Coverage is the share of the target cohort vaccinated, as estimated by WHO and UNICEF each July from the country's reports, surveys and other evidence, shown beside what the country itself reported. Reported cases are what the national surveillance system sent to WHO; they are a floor, not a count of infections. Every row carries a grade; hover or focus it for the reason, or read how grades are assigned.
Vaccination coverage
| Vaccine | Latest estimate | Country-reported | Trend since 2000 | Data quality |
|---|---|---|---|---|
| BCGTuberculosis vaccine at birth | 96%1996 · WHO/UNICEF estimate | 96% | too few points | D · poor |
| DTP1First dose of diphtheria-tetanus-pertussis | 99%2025 · WHO/UNICEF estimate | 98.9% | A · strong | |
| DTP3Third dose of diphtheria-tetanus-pertussis (the WHO benchmark of a working programme) | 99%2025 · WHO/UNICEF estimate | 98.5% | A · strong | |
| IPV1First dose of inactivated polio vaccine | 99%2025 · WHO/UNICEF estimate | 98.9% | A · strong | |
| IPV completeInactivated polio vaccine, complete primary series | 99%2025 · WHO/UNICEF estimate | 98.5% | C · weak | |
| MCV1First dose of measles-containing vaccine | 92%2025 · WHO/UNICEF estimate | 91.9% | A · strong | |
| MCV2Second dose of measles-containing vaccine | 89%2025 · WHO/UNICEF estimate | 89.0% | A · strong | |
| RCV1First dose of rubella-containing vaccine | 92%2025 · WHO/UNICEF estimate | 91.9% | A · strong | |
| HepB3Third dose of hepatitis B vaccine | 99%2025 · WHO/UNICEF estimate | 98.5% | A · strong | |
| HepB birthHepatitis B birth dose within 24 hours | 100%2025 · Administrative (country-reported) | 100% | D · poor | |
| Hib3Third dose of Haemophilus influenzae type b vaccine | 99%2025 · WHO/UNICEF estimate | 98.5% | A · strong | |
| PCV1Pneumococcal conjugate vaccine, first dose | 97.4%2025 · Administrative (country-reported) | 97.4% | D · poor | |
| PCV completePneumococcal conjugate vaccine, final dose of the schedule | 97%2025 · WHO/UNICEF estimate | 96.8% | C · weak | |
| RotaCRotavirus vaccine, complete series | —% · Administrative (country-reported) | — | too few points | no data |
| Yellow feverYellow fever vaccine (countries at risk) | —% · Administrative (country-reported) | — | too few points | no data |
| MenAMeningococcal A conjugate (meningitis belt) | 91.8%2021 · Administrative (country-reported) | 91.8% | too few points | D · poor |
| JEJapanese encephalitis vaccine (countries at risk) | —% · Administrative (country-reported) | — | too few points | no data |
| TCVTyphoid conjugate vaccine | —% · Administrative (country-reported) | — | too few points | no data |
| PABProtection at birth against neonatal tetanus (maternal tetanus doses) | —% · Administrative (country-reported) | — | too few points | no data |
| HPV dose 1, girlsHPV programme coverage, first dose, girls | 95%2025 · WHO/UNICEF estimate | — | B · good | |
| HPV complete, girlsHPV programme coverage, complete series, girls | 75%2025 · WHO/UNICEF estimate | — | B · good | |
| HPV dose 1, boysHPV programme coverage, first dose, boys | 70%2025 · WHO/UNICEF estimate | — | D · poor |
Reported vaccine-preventable disease
| Disease | Reported cases | Incidence rate | Trend since 2000 | Data quality |
|---|---|---|---|---|
| Measles all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | A · strong | |
| Rubella all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Congenital rubella syndrome all countries · vaccine evidence | 02025 | 0per 10,000 live births | C · weak | |
| Mumps all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | A · strong | |
| Pertussis (whooping cough) all countries · vaccine evidence | 82025 | 14.7per 1,000,000 total population | A · strong | |
| Diphtheria all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Tetanus (total) all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Neonatal tetanus all countries · vaccine evidence | 02025 | 0per 1,000 live births | B · good | |
| Polio (paralytic) all countries · vaccine evidence | 02022 | 0per 1,000,000 <15 population | D · poor | |
| Yellow fever all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | C · weak | |
| Japanese encephalitis all countries · vaccine evidence | 02021 | 0per 1,000,000 total population | D · poor | |
| Invasive meningococcal disease all countries · vaccine evidence | 12025 | 1.8per 1,000,000 total population | C · weak | |
| Typhoid all countries · vaccine evidence | 12025 | 1.8per 1,000,000 total population | B · good |
National schedule (latest WHO listing)
Show the schedule (40 rows)
| Vaccine | Dose | Age | Target group | Comment |
|---|---|---|---|---|
| BCGBCG (Baccille Calmette Guérin) vaccine | 1 | B | Risk group(s) | Babies of parents hailing from high-risk TB countriess |
| COVID19COVID-19 vaccine | 1 | Adults | All adults, all older adults | |
| COVID19COVID-19 vaccine | 1 | General/routine | All children and adolescents | |
| COVID19COVID-19 vaccine | 1 | Health workers | Health and care workers | |
| COVID19COVID-19 vaccine | 1 | Pregnant women | Pregnant women | |
| COVID19COVID-19 vaccine | 1 | Risk group(s) | Children and adolescents with chronic condition, adults with chronic conditions, older adults with chronic conditions, other groups | |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 1 | M2 | General/routine | |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 2 | M3 | General/routine | |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 3 | M4 | General/routine | |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 4 | M18 | General/routine | |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 1 | B | Risk group(s) | B - only to children of Hep B and / or C positive parents |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 2 | W4 | Risk group(s) | B - only to children of Hep B and / or C positive parents |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 3 | W8 | Risk group(s) | B - only to children of Hep B and / or C positive parents |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 4 | M12 | Risk group(s) | B - only to children of Hep B and / or C positive parents |
| HPV9HPV-9 (Human papillomavirus 9-valent) vaccine | 1 | Y12 | HPV administered to females and males | As of year 2023, females and males. All people born as of the year 2000 are eligible for free HPV vaccination. Currently we are doing a catch up for males born between 2000 and 2005 |
| HPV9HPV-9 (Human papillomavirus 9-valent) vaccine | 2 | +M6 | HPV administered to females and males | As of year 2023, females and males. All people born as of the year 2000 are eligible for free HPV vaccination. Currently we are doing a catch up for males born between 2000 and 2005 |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | >Y18 | Adults | and older adults over 65 years |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Health workers | Health and care workers | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Pregnant women | Pregnant women | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Risk group(s) | Adults with chronic conditions, residents living in long-term care facilities | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | >=M6 | General/routine | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | Risk group(s) | Children with chronic diseases | |
| MEN_ACYW_135CONJMeningococcal ACYW conjugate vaccine | 1 | M3 | General/routine | All children born from 2020 onwards are eligible for free Men ACWY in infancy and those born as of 2006 can take it for free once they turn 14. |
| MEN_ACYW_135CONJMeningococcal ACYW conjugate vaccine | 2 | M13 | General/routine | All children born from 2020 onwards are eligible for free Men ACWY in infancy and those born as of 2006 can take it for free once they turn 14. |
| MEN_ACYW_135CONJMeningococcal ACYW conjugate vaccine | 3 | Y14 | General/routine | All children born from 2020 onwards are eligible for free Men ACWY in infancy and those born as of 2006 can take it for free once they turn 14. |
| MEN_BMeningococcal B vaccine | 1 | M2 | General/routine | |
| MEN_BMeningococcal B vaccine | 2 | M4 | General/routine | |
| MEN_BMeningococcal B vaccine | 3 | M12 | General/routine | |
| MMRMMR (Measles, mumps and rubella) vaccine | 1 | M13 | General/routine | |
| MMRMMR (Measles, mumps and rubella) vaccine | 2 | Y3-Y4 | General/routine | |
| MPOXMpox (monkeypox) vaccine | 1 | >=Y18 | Risk group(s) | there are 2 categories of people eligible for M-pox vaccine -single doses to anyone demmed at risk through sexual history taking by GU-clinic physicians and 2 dose schedule to PLWH as prescribed by HIV clinic physicians. |
| PCV10PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine | 1 | M2 | General/routine | All children born in 2016 onwards and aged less than 5 years old |
| PCV10PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine | 2 | M4 | General/routine | All children born in 2016 onwards and aged less than 5 years old |
| PCV10PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine | 3 | M12 | General/routine | All children born in 2016 onwards and aged less than 5 years old |
| PCV20PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine | 1 | >=Y18 | Adults | All children with speficific medical conditions making them at higher risk of severe pneumococcal disease. The PCV 20 is also offered free of charge to all adults 18+,on a voluntary basis, it is especially recommended in people with chronic medical conditions that make them at higher risk of severe pneumococcal disease. |
| PCV20PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine | 1 | M2 | Risk group(s) | All children with speficific medical conditions making them at higher risk of severe pneumococcal disease. The PCV 20 is also offered free of charge to all adults 18+,on a voluntary basis, it is especially recommended in people with chronic medical conditions that make them at higher risk of severe pneumococcal disease. |
| PCV20PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine | 2 | M3 | Risk group(s) | All children with speficific medical conditions making them at higher risk of severe pneumococcal disease. The PCV 20 is also offered free of charge to all adults 18+,on a voluntary basis, it is especially recommended in people with chronic medical conditions that make them at higher risk of severe pneumococcal disease. |
| PCV20PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine | 3 | M4 | Risk group(s) | All children with speficific medical conditions making them at higher risk of severe pneumococcal disease. The PCV 20 is also offered free of charge to all adults 18+,on a voluntary basis, it is especially recommended in people with chronic medical conditions that make them at higher risk of severe pneumococcal disease. |
| PCV20PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine | 4 | M12 | Risk group(s) | All children with speficific medical conditions making them at higher risk of severe pneumococcal disease. The PCV 20 is also offered free of charge to all adults 18+,on a voluntary basis, it is especially recommended in people with chronic medical conditions that make them at higher risk of severe pneumococcal disease. |
| TDIPV_STd-IPV (Tetanus, diphtheria for older children and adults and IPV) vaccine | 5 | Y14 | General/routine |
Compare schedules across 31 countries on the schedule hub.
Data and sources
- Download this country's data (JSON): every year, every antigen and disease, with the grade reasons.
- Coverage: WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) and country-reported administrative/official coverage, from the WHO Immunization Data Portal export downloaded 21 October 2026.
- Reported cases and incidence: WHO/UNICEF Joint Reporting Form, same export. Incidence denominators are stated per row.
- Schedule: WHO vaccine-schedule export, latest listing year.